Shares of ImmunityBio touched a 52-week low after the company received a refusal-to-file letter from the Food and Drug Administration for a supplemental biologics license application for ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

EFF leader Julius Malema has been denied a visa to travel to the United Kingdom, prompting accusations of political silencing ...

If you are planning to apply for a Schengen visa, here is a list of some of the most commonly made mistakes that has led to ...

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior ...

CESTAT remits power project interest waiver case back to Chief Commissioner, citing unreasoned rejection and violation of ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...